PDS Biotechnology Corporation (PDSB)
NASDAQ$1.23
Market Cap
$54.85M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
329 of 924
Rank in Industry
191 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PDSB Insider Trading Activity
PDSB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $50,001 | 2 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Glover Stephen C. | director | 1 | $25,001 | 0 | $0 | $25,001 |
| Freitag Gregory Gene | director | 1 | $25,000 | 0 | $0 | $25,000 |
About PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for …
Insider Activity of PDS Biotechnology Corporation
Over the last 12 months, insiders at PDS Biotechnology Corporation have bought $50,001 and sold $0 worth of PDS Biotechnology Corporation stock.
On average, over the past 5 years, insiders at PDS Biotechnology Corporation have bought $263,313 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Glover Stephen C. (director) — $25,001. Freitag Gregory Gene (director) — $25,000.
The last purchase of 15,061 shares for transaction amount of $25,001 was made by Glover Stephen C. (director) on 2025‑02‑28.
List of Insider Buy and Sell Transactions, PDS Biotechnology Corporation
| 2025-02-28 | Glover Stephen C. | director | 15,061 0.0504% | $1.66 | $25,001 | -7.52% | ||
| 2025-02-28 | Freitag Gregory Gene | director | 15,060 0.0504% | $1.66 | $25,000 | -7.52% | ||
| 2021-12-13 | HILL MATTHEW C | 3,100 0.012% | $8.99 | $27,860 | -41.56% | |||
| 2021-06-16 | Bloomquist DeLyle W | 10,000 0.0456% | $9.88 | $98,778 | -4.17% | |||
| 2021-06-15 | Glover Steve C | 5,882 0.0235% | $8.50 | $49,997 | -2.50% | |||
| 2021-06-15 | Freitag Gregory Gene | 5,882 0.0235% | $8.50 | $49,997 | -2.50% | |||
| 2021-06-15 | VAN VOORHEES SETH | 17,647 0.0704% | $8.50 | $150,000 | -2.50% | |||
| 2021-06-15 | Ali-Jackson Kamil | 11,764 0.0469% | $8.50 | $99,994 | -2.50% | |||
| 2018-03-22 | Sale | Macdonald R. Loch | Chief Scientific Officer | 5,000 0.0161% | $16.41 | $82,050 | -94.86% | |
| 2018-03-21 | Sale | Macdonald R. Loch | Chief Scientific Officer | 5,000 0.0159% | $16.52 | $82,600 | -94.94% | |
| 2018-03-20 | Sale | Macdonald R. Loch | Chief Scientific Officer | 10,000 0.0322% | $16.47 | $164,700 | -94.85% | |
| 2018-03-19 | Sale | Macdonald R. Loch | Chief Scientific Officer | 5,000 0.0161% | $16.59 | $82,950 | -94.88% | |
| 2018-03-02 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0159% | $15.08 | $75,400 | -94.24% | |
| 2018-03-01 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0161% | $14.95 | $74,725 | -94.13% | |
| 2018-02-23 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0158% | $15.37 | $76,850 | -94.34% | |
| 2018-02-22 | Sale | Macdonald R. Loch | Chief Scientific Officer | 5,000 0.0151% | $14.49 | $72,450 | -94.25% | |
| 2018-02-22 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0161% | $15.42 | $77,100 | -94.25% | |
| 2018-02-21 | Sale | Macdonald R. Loch | Chief Scientific Officer | 10,000 0.0304% | $13.82 | $138,200 | -93.91% | |
| 2018-02-20 | Sale | Macdonald R. Loch | Chief Scientific Officer | 10,000 0.0323% | $13.79 | $137,850 | -93.48% | |
| 2018-02-02 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0163% | $12.96 | $64,800 | -92.76% |
Total: 67
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Glover Stephen C. | director | 78851 0.1768% | $96,986.73 | 2 | 0 | <0.0001% |
| Freitag Gregory Gene | director | 61213 0.1373% | $75,291.99 | 2 | 0 | <0.0001% |
| HEALY JAMES | director | 2852711 6.3977% | $3.51M | 2 | 0 | <0.0001% |
| Hove Anders D | director | 2021917 4.5345% | $2.49M | 1 | 0 | <0.0001% |
| BARER SOL J | director | 632810 1.4192% | $778,356.30 | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$6,787,959 | 35 | 49.84% | $60.62M | |
$459,011,221 | 33 | 33.04% | $57.94M | |
$18,274,594 | 22 | -26.07% | $49.68M | |
PDS Biotechnology Corporation (PDSB) | $26,736,140 | 20 | -18.64% | $54.85M |
$47,863,113 | 17 | -22.07% | $56.72M |
PDSB Institutional Investors: Active Positions
| Increased Positions | 25 | +35.21% | 606,077 | +13.95% |
| Decreased Positions | 29 | -40.85% | 696,930 | -16.05% |
| New Positions | 8 | New | 118,301 | New |
| Sold Out Positions | 13 | Sold Out | 201,471 | Sold Out |
| Total Postitions | 67 | -5.63% | 4M | -2.09% |
PDSB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $2,003.00 | 4.07% | 1.51M | -15,731 | -1.03% | 2024-12-31 |
| Blackrock, Inc. | $696.00 | 1.41% | 523,142 | +34,846 | +7.14% | 2024-12-31 |
| Geode Capital Management, Llc | $555.00 | 1.13% | 417,217 | +2,104 | +0.51% | 2024-12-31 |
| Susquehanna International Group, Llp | $328.00 | 0.67% | 246,977 | +112,717 | +83.95% | 2024-12-31 |
| Citadel Advisors Llc | $293.00 | 0.6% | 220,215 | +105,233 | +91.52% | 2024-12-31 |
| Blair William & Co/Il | $209.00 | 0.43% | 157,500 | +35,757 | +29.37% | 2024-12-31 |
| State Street Corp | $177.00 | 0.36% | 133,333 | +21,500 | +19.23% | 2024-12-31 |
| Millennium Management Llc | $168.00 | 0.34% | 126,416 | -107,793 | -46.02% | 2024-12-31 |
| Renaissance Technologies Llc | $133.00 | 0.27% | 100,000 | +76,800 | +331.03% | 2024-12-31 |
| Northern Trust Corp | $110.00 | 0.22% | 82,532 | -10,261 | -11.06% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.